Los Angeles Capital Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Los Angeles Capital Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-13,114	Closed	-$489K	–	1634
2021 Q2	$489K	Sell	13,114 -8,325	-39%	-$255K	﹤0.01%	1173
2021 Q1	$548K	Sell	21,439 -27,115	-56%	-$693K	﹤0.01%	1175
2020 Q4	$1.07M	Sell	48,554 -2,595	-5%	-$57.2K	﹤0.01%	917
2020 Q3	$920K	Sell	51,149 -4,466	-8%	-$92.5K	﹤0.01%	853
2020 Q2	$1.41M	Sell	55,615 -11,389	-17%	-$245K	0.01%	719
2020 Q1	$1.23M	Buy	67,004 +42,312	+171%	+$822K	0.01%	662
2019 Q4	$544K	Buy	24,692 +12,712	+106%	+$256K	﹤0.01%	995
2019 Q3	$172K	Hold	11,980	–	–	﹤0.01%	1219
2019 Q2	$189K	Hold	11,980	–	–	﹤0.01%	1296
2019 Q1	$176K	Buy	+11,980	New	+$138K	﹤0.01%	1321

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Los Angeles Capital Management's DRNA Position: Q3 2021 in Review

Los Angeles Capital Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2021, closing a stake of 13,114 shares — an estimated $489K sold.

Los Angeles Capital Management first reported a position in DRNA in Q1 2019 and held it in 10 quarters. The position peaked at $1.41M in Q2 2020. 173 funds tracked by Wall St. Rank hold DRNA as of Q3 2021.

Los Angeles Capital Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
Los Angeles Capital Management sold 13,114 Dicerna Pharmaceuticals, Inc. shares in Q3 2021, an estimated $489K.
Los Angeles Capital Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2019 and held it in 10 quarters.
Los Angeles Capital Management's Dicerna Pharmaceuticals, Inc. position peaked at $1.41M in Q2 2020.
173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2021.

Based on Los Angeles Capital Management's 13F filing for Q3 2021, filed 5 Nov 2021.